Korsana Biosciences (KRSA) vs Zenas BioPharma (ZBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Korsana Biosciences (KRSA) has outperformed Zenas BioPharma (ZBIO) over the past year, gaining 90.0% versus a gain of 1.3%. Zenas BioPharma is the larger company by market cap ($1.78 billion vs $1.54 billion), about 1.2 times the size. Korsana Biosciences converts more of its revenue into profit, with a net margin of -170.1% versus -3777.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KRSA | ZBIO |
|---|---|---|
| Share price | $33.92 | $27.26 |
| Market cap | $1.54B | $1.78B |
| 1-day change | +1.22% | +3.89% |
| YTD return | +276.94% | -27.73% |
| 1-year return | +89.97% | +1.31% |
| 5-year return | -91.10% | — |
| EPS (TTM) | $-7.07 | $-9.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.07M | $10.00M |
| Revenue growth (YoY) | +3.70% | +100.00% |
| Net income (latest FY) | $-3.53M | $-377.74M |
| Operating margin | -239.78% | -3830.57% |
| Net margin | -170.11% | -3777.37% |
| 52-week high | $59.36 | $44.60 |
| 52-week low | $7.19 | $13.50 |
| Distance from 52-week high | -42.86% | -38.88% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +29.72% | +75.64% |
| Average volume | 32.06K | 733.34K |
| Shares outstanding | 45.54M | 65.18M |
| Employees | 19 | 167 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KRSA has outperformed ZBIO by 88.7 percentage points over the past year.
- Korsana Biosciences is more profitable, keeping -170.1 cents of every revenue dollar as net income versus -3777.4 cents for Zenas BioPharma.
- Zenas BioPharma grew revenue faster in its latest fiscal year (+100.00% vs +3.70%).
About Korsana Biosciences
KRSA stock →Korsana Biosciences, Inc. develops therapeutic antibodies for the treatment of neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees
About Zenas BioPharma
ZBIO stock →Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus.
Health Care · Biotechnology: Pharmaceutical Preparations · 167 employees
KRSA vs ZBIO FAQ
Which is bigger, Korsana Biosciences or Zenas BioPharma?
Zenas BioPharma (ZBIO) is larger, with a market capitalization of $1.78B compared with $1.54B for Korsana Biosciences (KRSA).
Which stock has performed better over the past year, KRSA or ZBIO?
KRSA returned +89.97% over the past 12 months, compared with +1.31% for ZBIO (price return, excluding dividends). Past performance does not predict future results.
Are Korsana Biosciences and Zenas BioPharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.